Regulation of airway inflammation by Siglec-8 and Siglec-9 sialoglycan ligand expression

Current Opinion in Allergy and Clinical Immunology

Volumn 16, Issue 1, 2016, Pages 24-30

  Schleimer, Robert P ^a   Schnaar, Ronald L ^b   Bochner, Bruce S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic rhinosinusitis; Eosinophil; Glycan; Mast cell; Siglec

Indexed keywords

SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN; SIALOGLYCOPROTEIN; SIGLEC 8; SIGLEC 9; UNCLASSIFIED DRUG; B LYMPHOCYTE ANTIGEN; LECTIN; LEUKOCYTE ANTIGEN; SIGLEC8 PROTEIN, HUMAN; SIGLEC9 PROTEIN, HUMAN;

ANTIGEN EXPRESSION; ANTIGEN FUNCTION; BASOPHIL; CHRONIC RHINOSINUSITIS; HUMAN; IN VIVO STUDY; MAST CELL; NEUTROPHIL; PNEUMONIA; PRIORITY JOURNAL; REGULATORY MECHANISM; RESPIRATORY TRACT INFLAMMATION; REVIEW; ANIMAL; CHRONIC DISEASE; GENE EXPRESSION REGULATION; IMMUNOLOGY; INFLAMMATION; NOSE MUCOSA; PATHOLOGY; RHINITIS; SINUSITIS;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; CHRONIC DISEASE; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; LECTINS; NASAL MUCOSA; RHINITIS; SIALIC ACID BINDING IMMUNOGLOBULIN-LIKE LECTINS; SINUSITIS;

EID: 84952865216     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000234     Document Type: Review

References (61)

1. Bhattacharyya N, Orlandi RR, Grebner J, Martinson M. Cost burden of chronic rhinosinusitis: A claims-based study. Otolaryngol Head Neck Surg 2011; 144:440-445.
2. Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012; 50:1-12.
3. Meltzer EO, Hamilos DL, Hadley JA, et al. Rhinosinusitis: Developing guidance for clinical trials. J Allergy Clin Immunol 2006; 118:S17-S61.
4. Akdis CA, Bachert C, Cingi C, et al. Endotypes and phenotypes of chronic rhinosinusitis: A PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol 2013; 131:1479-1490.
5. Takabayashi T, Kato A, Peters AT, et al. Excessive fibrin deposition in nasal polyps caused by fibrinolytic impairment through reduction of tissue plasminogen activator expression. Am J Respir Crit Care Med 2013; 187:49-57.
6. Hulse KE, Stevens WW, Tan BK, Schleimer RP. Pathogenesis of nasal polyposis. Clin Exp Allergy 2015; 45:328-346.
7. Schleimer RP, Kato A, Kern RC. Eosinophils and chronic rhinosinusitis. In: Rosenberg HF, Lee JJ, editors. Eosinophils in health and disease. Amsterdam: Elsevier; 2012. pp. 508-518.
8. Zhang N, Holtappels G, Claeys C, et al. Pattern of inflammation and impact of Staphylococcus aureus enterotoxins in nasal polyps from southern China. Am J Rhinol 2006; 20:445-450.
9. Mahdavinia M, Suh LA, Carter RG, et al. Increased noneosinophilic nasal polyps in chronic rhinosinusitis in US second-generation Asians suggest genetic regulation of eosinophilia. J Allergy Clin Immunol 2015; 135:576- 579.
10. Gevaert P, Van Bruaene N, Cattaert T, et al. Mepolizumab, a humanized anti- IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol 2011; 128:989-995.
11. Takabayashi T, Kato A, Peters AT, et al. Glandular mast cells with distinct phenotype are highly elevated in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol 2012; 130:410-420.
12. Mahdavinia M, Carter RG, Ocampo CJ, et al. Basophils are elevated in nasal polyps of patients with chronic rhinosinusitis without aspirin sensitivity. J Allergy Clin Immunol 2014; 133:1759-1763.
13. Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 2013; 131:110-116.
14. Crocker PR, Clark EA, Filbin M, et al. Siglecs: A family of sialic-acid binding lectins. Glycobiology 1998; 8.
15. Bochner BS. Novel therapies for eosinophilic disorders. Immunol Allergy Clin North Am 2015; 35:577-598.
16. Macauley MS, Crocker PR, Paulson JC. Siglec-mediated regulation of immune cell function in disease. Nat Rev Immunol 2014; 14:653-666.
17. Tateno H, Crocker PR, Paulson JC. Mouse Siglec-F and human Siglec-8 are functionally convergent paralogs that are selectively expressed on eosinophils and recognize 6'-sulfo-sialyl Lewis X as a preferred glycan ligand. Glycobiology 2005; 15:1125-1135.
18. Bochner BS. Siglec-8 on human eosinophils and mast cells, and Siglec-F on murine eosinophils, are functionally related inhibitory receptors. Clin Exp Allergy 2009; 39:317-324.
19. Zhang JQ, Biedermann B, Nitschke L, Crocker PR. The murine inhibitory receptor mSiglec-E is expressed broadly on cells of the innate immune system whereas mSiglec-F is restricted to eosinophils. Eur J Immunol 2004; 34:1175-1184.
20. Stevens WW, Kim TS, Pujanauski LM, et al. Detection and quantitation of eosinophils in the murine respiratory tract by flow cytometry. J Immunol Methods 2007; 327:63-74.
21. Nutku E, Aizawa H, Hudson SA, Bochner BS. Ligation of Siglec-8: A selective mechanism for induction of human eosinophil apoptosis. Blood 2003; 101:5014-5020.
22. Nutku E, Hudson SA, Bochner BS. Mechanism of Siglec-8-induced human eosinophil apoptosis: Role of caspases and mitochondrial injury. Biochem Biophys Res Commun 2005; 336:918-924.
23. Nutku-Bilir E, Hudson SA, Bochner BS. Interleukin-5 priming of human eosinophils alters Siglec-8 mediated apoptosis pathways. Am J Respir Cell Mol Biol 2008; 38:121-124.
24. von Gunten S, Yousefi S, Seitz M, et al. Siglec-9 transduces apoptotic and nonapoptotic death signals into neutrophils depending on the proinflammatory cytokine environment. Blood 2005; 106:1423-1431.
25. von Gunten S, Schaub A, Vogel M, et al. Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations. Blood 2006; 108:4255-4259.
26. Hudson SA, Bovin N, Schnaar RL, et al. Eosinophil-selective binding and proapoptotic effect in vitro of a synthetic Siglec-8 ligand, polymeric 6'-sulfated sialyl Lewis X. J Pharmacol Exp Ther 2009; 330:608-612.
27. Na HJ, Hudson SA, Bochner BS. IL-33 enhances Siglec-8 mediated apoptosis of human eosinophils. Cytokine 2012; 57:169-174.
28. Kano G, Almanan M, Bochner BS, Zimmermann N. Mechanism of Siglec-8- mediated cell death in IL-5-activated eosinophils: Role for reactive oxygen species-enhanced MEK/ERK activation. J Allergy Clin Immunol 2013; 132:437-445.
29. Yokoi H, Choi OH, Hubbard W, et al. Inhibition of FceRI-dependent mediator release and calcium flux from human mast cells by Siglec-8 engagement. J Allergy Clin Immunol 2008; 121:499-505.
30. Ando M, Tu W, Nishijima K, Iijima S. Siglec-9 enhances IL-10 production in macrophages via tyrosine-based motifs. Biochem Biophys Res Commun 2008; 369:878-883.
31. Chen GY, Brown NK, Wu W, et al. Broad and direct interaction between TLR and Siglec families of pattern recognition receptors and its regulation by Neu1. Elife 2014; 3:e04066.
32. Zimmermann N, McBride ML, Yamada Y, et al. Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils. Allergy 2008; 63:1156-1163.
33. Mao H, Kano G, Hudson SA, et al. Mechanisms of Siglec-F-induced eosinophil apoptosis: A role for caspases but not for SHP-1, Src kinases, NADPH oxidase or reactive oxygen. PLoS One 2013; 8:e68143.
34. Boyd CR, Orr SJ, Spence S, et al. Siglec-E is up-regulated and phosphorylated following lipopolysaccharide stimulation in order to limit TLR-driven cytokine production. J Immunol 2009; 183:7703-7709.
35. Laubli H, Pearce OM, Schwarz F, et al. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer. Proc Natl Acad Sci U S A 2014; 111:14211-14216.
36. Jandus C, Boligan KF, Chijioke O, et al. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J Clin Invest 2014; 124:1810-1820.
37. Schwarz F, Pearce OM, Wang X, et al. Siglec receptors impact mammalian lifespan by modulating oxidative stress. Elife 2015; 4:e06184.
38. Bochner BS, Alvarez RA, Mehta P, et al. Glycan array screening reveals a candidate ligand for Siglec-8. J Biol Chem 2005; 280:4307-4312.
39. Kiwamoto T, Katoh T, Evans CM, et al. Endogenous airway mucins carry glycans that bind Siglec-F and induce eosinophil apoptosis. J Allergy Clin Immunol 2015; 135:1329-1340.
40. Song DJ, Cho JY, Lee SY, et al. Anti-Siglec-F antibody reduces allergeninduced eosinophilic inflammation and airway remodeling. J Immunol 2009; 183:5333-5341.
41. Guo JP, Brummet ME, Myers AC, et al. Characterization of expression of glycan ligands for Siglec-F in normal mouse lungs. Am J Respir Cell Mol Biol 2011; 44:238-243.
42. Zhang M, Angata T, Cho JY, et al. Defining the in vivo function of Siglec-F, a CD33-related Siglec expressed on mouse eosinophils. Blood 2007; 109:4280-4287.
43. Suzukawa M, Miller M, Rosenthal P, et al. Sialyltransferase ST3Gal-III regulates Siglec-F ligand formation and eosinophilic lung inflammation in mice. J Immunol 2013; 190:5939-5948.
44. Kiwamoto T, Brummet ME, Wu F, et al. Mice deficient in the St3gal3 gene product a2, 3 sialyltransferase (ST3Gal-III) exhibit enhanced allergic eosinophilic airway inflammation. J Allergy Clin Immunol 2014; 133:240-247.
45. Kiwamoto T, Katoh T, Tiemeyer M, Bochner BS. The role of lung epithelial ligands for Siglec-8 and Siglec-F in eosinophilic inflammation. Curr Opin Allergy Clin Immunol 2013; 13:106-111.
46. Fahy JV, Dickey BF. Airway mucus function and dysfunction. N Engl J Med 2010; 363:2233-2247.
47. Wickstrom C, Davies JR, Eriksen GV, et al. MUC5B is a major gel-forming, oligomeric mucin from human salivary gland, respiratory tract and endocervix: identification of glycoforms and C-terminal cleavage. Biochem J 1998; 334:685-693.
48. Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 2011; 364:1503-1512.
49. Young HW, Williams OW, Chandra D, et al. Central role of Muc5ac expression in mucous metaplasia and its regulation by conserved 5' elements. Am J Respir Cell Mol Biol 2007; 37:273-290.
50. Henke MO, Renner A, Huber RM, et al. MUC5AC and MUC5B mucins are decreased in cystic fibrosis airway secretions. Am J Respir Cell Mol Biol 2004; 31:86-91.
51. Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009; 180:388-395.
52. Kirkham S, Kolsum U, Rousseau K, et al. MUC5B is the major mucin in the gel phase of sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 178:1033-1039.
53. Kim DH, Chu HS, Lee JY, et al. Up-regulation of MUC5AC andMUC5B mucin genes in chronic rhinosinusitis. Arch Otolaryngol Head Neck Surg 2004; 130:747-752.
54. McMillan SJ, Sharma RS, McKenzie EJ, et al. Siglec-E is a negative regulator of acute pulmonary neutrophil inflammation and suppresses CD11b b2- integrin-dependent signaling. Blood 2013; 121:2084-2094.
55. McMillan SJ, Sharma RS, Richards HE, et al. Siglec-E promotes b2-integrindependent NADPH oxidase activation to suppress neutrophil recruitment to the lung. J Biol Chem 2014; 289:20370-20376.
56. Jia Y, Yu H, Fernandes SM, et al. Expression of ligands for Siglec-8 and Siglec-9 in human airways and airway cells. J Allergy Clin Immunol 2015; 135:799-810.
57. Tomioka Y, Morimatsu M, Nishijima K, et al. A soluble form of Siglec-9 provides an antitumor benefit against mammary tumor cells expressing MUC1 in transgenic mice. Biochem Biophys Res Commun 2014; 450:532-537.
58. Tanida S, Akita K, Ishida A, et al. Binding of the sialic acid-binding lectin, Siglec-9, to the membrane mucin, MUC1, induces recruitment of b-catenin and subsequent cell growth. J Biol Chem 2013; 288:31842- 31852.
59. Kiwamoto T, Kawasaki N, Paulson JC, Bochner BS. Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions. Pharmacol Ther 2012; 135:327-336.
60. Spence S, Greene MK, Fay F, et al. Targeting Siglecs with a sialic aciddecorated nanoparticle abrogates inflammation. Sci Transl Med 2015; 7:303ra140.
61. von Gunten S, Simon HU. Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: implications for the clinical use of intravenous immunoglobulins (IVIg). Autoimmun Rev 2008; 7:453- 456.